Drugs for Constipation and Diarrhoea

Laxatives — Classification

Bulk-forming: psyllium, methylcellulose, bran. Osmotic: lactulose, PEG, Mg(OH)2/sulfate, sorbitol. Stimulant: bisacodyl, senna, castor oil. Stool softener: docusate sodium. Lubricant: mineral oil. Newer: lubiprostone(Cl- channel activator), linaclotide(guanylate cyclase-C agonist), prucalopride(5-HT4 agonist, prokinetic).

Laxatives — Mechanism

Bulk-forming: indigestible fibre absorbs water → ↑stool bulk/softness → mechanical peristalsis stimulation via stretch. Most PHYSIOLOGICAL(mimics dietary fibre), 1st-line/safest for chronic constipation.

Osmotic: poorly-absorbed solutes retain water osmotically. Lactulose: synthetic disaccharide, unabsorbed/unmetabolized by human enzymes → colonic bacteria ferment→short-chain fatty acids(more osmotic activity+↓colonic pH). SEPARATE use: hepatic encephalopathy — acidified colon favours NH3→NH4+ conversion(non-absorbable) → traps nitrogen for excretion, INDEPENDENT of laxative effect — genuinely distinct pharmacological application of same drug. PEG: pure osmotic water retention, no fermentation/electrolyte disturbance → preferred routine use + bowel prep(high dose, colonoscopy).

Stimulant: directly stimulates colonic myenteric plexus + ↑fluid/electrolyte secretion → MOST rapid effective class. Reserved short-term/intermittent(debated tolerance/“cathartic colon” concern with chronic use) + cramping common at effective dose.

Docusate: anionic surfactant, ↓stool surface tension→water/lipid penetration→softening. MILD effect — prophylaxis against straining(post-surgical/MI/haemorrhoids), NOT treatment for established constipation.

Lubiprostone: activates intestinal ClC-2 chloride channels → Cl—rich fluid secretion. TARGETED secretory mechanism(distinct from osmotic). Chronic idiopathic constipation + opioid-induced constipation.

Linaclotide: guanylate cyclase-C agonist → ↑cGMP → activates CFTR(same channel defective in CF) → ↑fluid secretion + SEPARATE ↓visceral pain-afferent activity. Constipation-predominant IBS(dual secretory+pain-modulating action addresses both symptoms).

Antidiarrhoeals — Classification

Opioid agonists(gut-selective): loperamide, diphenoxylate(+atropine). Bile acid sequestrant: cholestyramine(bile-acid-induced diarrhoea specifically). Bismuth subsalicylate. Octreotide(secretory diarrhoea). ORS — not antidiarrhoeal mechanism, but SINGLE MOST IMPORTANT intervention globally.

Antidiarrhoeals — Mechanism

Loperamide: μ-opioid agonist on ENS(same μ mechanism as Opioid Analgesics, here GI-only). Doesn’t cross BBB appreciably at therapeutic dose(P-gp substrate, actively pumped out) → NO central analgesic/euphoric/dependence effect despite being an opioid. Overwhelmed at VERY HIGH(supratherapeutic/misuse) doses → genuine CNS opioid effects + CARDIOTOXICITY(QT prolongation) — real, increasingly-recognized loperamide misuse risk.

Diphenoxylate: also μ-agonist on gut motility, but DOES cross BBB at higher doses + genuine abuse potential → combined with SUBTHERAPEUTIC atropine — NOT for therapeutic anticholinergic effect, but as ABUSE DETERRENT(supratherapeutic dose for euphoria also delivers unpleasant atropine dose) — “deliberately added deterrent, not therapeutic ingredient,” distinct from ordinary combination logic.

Bismuth subsalicylate: multiple actions — direct antimicrobial vs some enteric pathogens + anti-inflammatory(salicylate component, aspirin-related) + some antisecretory. Mild traveller’s diarrhoea, adjunct.

Octreotide: somatostatin analogue, inhibits GI hormone secretion(gastrin, VIP, insulin, glucagon) + direct ↓intestinal fluid secretion. Specific value: secretory diarrhoea from hormone-secreting tumours(VIPoma, carcinoid) — driven by excess hormone-stimulated secretion, genuinely different mechanism/indication from opioid-agonist antidiarrhoeals.

HIGH-YIELD CAUTION: Antimotility Agents in Invasive/Inflammatory Diarrhoea

Loperamide/diphenoxylate CONTRAINDICATED/significant caution in diarrhoea from INVASIVE organisms(Shigella, Salmonella, EIEC, C. diff) — slowed transit → ↑pathogen/toxin-bowel contact time → ↑toxin absorption → can precipitate TOXIC MEGACOLON(real, dangerous, not theoretical). SINGLE MOST IMPORTANT prescribing caution in topic — reflexive antimotility use without considering invasive/inflammatory cause = real examined clinical error.

Clinical Relevance

2 organizing distinctions: LAXATIVES — mechanism predicts onset speed+appropriate use(bulk-forming=chronic safe; stimulant=rapid short-term; osmotic PEG=bowel prep). ANTIDIARRHOEALS — loperamide/diphenoxylate CNS-penetration distinction(P-gp-excluded or not) explains WHY one needs abuse-deterrent co-formulation and other doesn’t; invasive-organism caution applies IDENTICALLY to both = highest-stakes point in topic — symptomatic relief without considering whether underlying cause makes that specific intervention dangerous.

Laxatives

Classification (by Mechanism)

1. Bulk-forming: psyllium, methylcellulose, bran
2. Osmotic: lactulose, polyethylene glycol (PEG), magnesium hydroxide/sulfate, sorbitol
3. Stimulant: bisacodyl, senna, castor oil (ricinoleic acid)
4. Stool softeners/emollient: docusate sodium
5. Lubricant: mineral oil
6. Newer/targeted agents: lubiprostone (chloride channel activator), linaclotide (guanylate cyclase-C agonist), prucalopride (5-HT4 agonist, prokinetic)

Mechanism of Action

Bulk-forming agents: indigestible fibre that absorbs water within the intestinal lumen, increasing stool bulk and softness, which mechanically stimulates peristalsis via stretch — the most physiological mechanism of this group, mimicking dietary fibre’s normal effect, and generally the first-line, safest option for chronic/simple constipation given the mildest adverse-effect profile of any laxative class.

Osmotic laxatives: poorly absorbed solutes that retain water in the intestinal lumen by osmosis — lactulose is a synthetic disaccharide, unabsorbed and unmetabolized by human enzymes, that reaches the colon intact where colonic bacteria ferment it to short-chain fatty acids (further contributing osmotic activity and lowering colonic pH); this colonic-acidification effect gives lactulose a genuinely separate, specific use in hepatic encephalopathy — the acidified colonic environment favours conversion of absorbable ammonia (NH3) to non-absorbable ammonium (NH4⁺), trapping nitrogen in the colon for excretion rather than allowing its absorption into the portal circulation, a mechanism entirely independent of its laxative effect and worth understanding as a genuinely distinct pharmacological application of the same drug. Polyethylene glycol works by pure osmotic water retention without fermentation or significant electrolyte disturbance, making it a preferred choice for routine use and for bowel preparation before colonoscopy (used at a much higher dose specifically for rapid, complete colonic evacuation).

Stimulant laxatives: directly stimulate colonic myenteric plexus neurons, increasing intestinal motility, and also increase colonic fluid/electrolyte secretion — the most rapidly effective class for acute constipation, but generally reserved for short-term/intermittent use given a genuinely debated (though less clearly established than once assumed) concern about tolerance and “cathartic colon” with chronic use, alongside more immediate cramping as a common adverse effect at effective doses.

Docusate sodium: an anionic surfactant, reducing stool surface tension and allowing water/lipid to penetrate and soften the stool — a genuinely mild effect, useful mainly as prophylaxis against straining (e.g. post-surgical, post-MI, or with haemorrhoids) rather than as treatment for established constipation.

Lubiprostone: activates intestinal type 2 chloride channels (ClC-2), increasing chloride-rich fluid secretion into the intestinal lumen — a genuinely targeted secretory mechanism distinct from simple osmotic water retention, used for chronic idiopathic constipation and opioid-induced constipation specifically.

Linaclotide: a guanylate cyclase-C agonist, increasing intracellular cGMP in intestinal epithelial cells, which activates the CFTR chloride channel (the same channel defective in cystic fibrosis) to increase intestinal fluid secretion, alongside a separate effect reducing visceral pain-sensing afferent nerve activity — used for constipation-predominant irritable bowel syndrome specifically, where this dual secretory-plus-pain-modulating action addresses both symptoms simultaneously.

Antidiarrhoeal Agents

Classification

1. Opioid agonists (gut-selective): loperamide, diphenoxylate (combined with atropine)
2. Bile acid sequestrant (for bile-acid-induced diarrhoea specifically): cholestyramine
3. Bismuth subsalicylate
4. Octreotide (for secretory diarrhoea, particularly hormone-secreting tumour-related)
5. Oral rehydration therapy (ORS) — not antidiarrhoeal in mechanism, but the single most important intervention for diarrhoeal illness globally

Mechanism of Action

Loperamide: a μ-opioid receptor agonist acting on the enteric nervous system, reducing intestinal motility (the same fundamental μ-receptor mechanism already described under Opioid Analgesics and Antagonists, here exploited purely for its GI effect) — critically, loperamide does not cross the blood-brain barrier appreciably at therapeutic doses (a substrate for P-glycoprotein, which actively pumps it back out of the CNS), giving it essentially no central analgesic/euphoric/dependence-producing effect despite being an opioid — a specific, high-yield distinction from other opioids, though this P-gp-mediated exclusion can be overwhelmed at very high (supratherapeutic/misuse) doses, where genuine CNS opioid effects and cardiotoxicity (QT prolongation) become possible, a real, increasingly-recognized risk with loperamide misuse specifically.

Diphenoxylate: also a μ-agonist acting on gut motility, but does cross the blood-brain barrier at higher doses and carries genuine abuse potential — the specific reason it’s formulated in combination with a subtherapeutic dose of atropine, deliberately included not for therapeutic anticholinergic effect but as an abuse deterrent (a supratherapeutic dose taken for euphoric effect would also deliver a distinctly unpleasant atropine dose, discouraging misuse) — a specific, frequently-examined “deliberately added deterrent, not a therapeutic ingredient” rationale worth distinguishing from ordinary combination-drug logic.

Bismuth subsalicylate: multiple proposed actions — direct antimicrobial effect against some enteric pathogens, anti-inflammatory action (from the salicylate component, structurally/mechanistically related to aspirin), and some antisecretory effect — used for mild traveller’s diarrhoea and as adjunct therapy.

Octreotide: a somatostatin analogue, inhibiting secretion of numerous GI hormones (gastrin, VIP, insulin, glucagon) and reducing intestinal fluid secretion directly — specifically valuable for severe secretory diarrhoea from hormone-secreting tumours (VIPoma, carcinoid syndrome) where the diarrhoea is driven by excess hormone-stimulated secretion rather than ordinary infectious/inflammatory mechanisms, a genuinely different indication and mechanism from the opioid-agonist antidiarrhoeals above.

A Specific, High-Yield Caution: Antimotility Agents in Invasive/Inflammatory Diarrhoea

Loperamide and diphenoxylate are contraindicated (or used with significant caution) in diarrhoea caused by invasive organisms (Shigella, Salmonella, enteroinvasive E. coli, C. difficile) — slowing intestinal transit in this setting prolongs contact time between the pathogen/toxin and the bowel wall, increases toxin absorption, and can precipitate toxic megacolon, a specific, genuinely dangerous complication rather than a theoretical concern — this is the single most important prescribing caution in the entire topic, since reflexively reaching for an antimotility agent for any diarrhoea, without first considering an invasive/inflammatory cause, is a real, examined clinical error.

Clinical Relevance

Two organizing distinctions run through this topic: within laxatives, mechanism (bulk/osmotic/stimulant/secretory) predicts both speed of onset and appropriate use case (bulk-forming for chronic/safe long-term use, stimulant for rapid short-term relief, osmotic PEG for bowel prep); within antidiarrhoeals, the loperamide/diphenoxylate central-nervous-system-penetration distinction (P-gp-excluded versus not) explains why one needs an abuse-deterrent co-formulation and the other doesn’t, while the invasive-organism caution applies identically to both and is the actual highest-stakes teaching point in the topic — reaching for symptomatic antimotility relief without first considering whether the underlying cause makes that specific intervention dangerous.

• Lactulose’s dual mechanism: osmotic laxative effect vs colonic ammonia-trapping in hepatic encephalopathy, shown as two separate pathways from the same drug.
• Loperamide vs diphenoxylate CNS-penetration comparison, explaining the atropine abuse-deterrent rationale.

Short Essays (2)

Short Answers (18)

Multiple Choice Questions (5)